Previous 10 | Next 10 |
MIAMI, March 09, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeut...
2023-03-08 16:34:00 ET Shares of drug and diagnostics company OPKO Health (NASDAQ: OPK) closed 8% higher Wednesday following news of a collaboration agreement with pharmaceutical giant Merck (NYSE: MRK) . While down from an intraday rally of more than 24%, the remaining gain...
2023-03-08 16:07:58 ET OPKO Health ( NASDAQ: OPK ) closed up 6.6% on Wednesday after signing a licensing deal with Merck to develop an Epstein-Barr virus vaccine together. The arrangement is between OPKO's ( OPK ) ModeX Therapeutics unit and Merck ( MRK ) for p...
2023-03-08 10:44:00 ET As savvy investors know, penny stocks can offer high returns if chosen wisely. These stocks, which trade for less than $5 per share, often represent small companies with high growth potential. But they also carry high risks due to their volatility and low liquidity. T...
2023-03-08 08:38:01 ET Opko Health's ( NASDAQ: OPK ) ModeX Therapeutics signed a worldwide license agreement with Merck ( NYSE: MRK ) to develop its preclinical Epstein-Barr Virus (EBV) vaccine candidate MDX-2201. EBV, also known as human herpesvirus 4, is a m...
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteins EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health...
Summary Losses continue to mount and revenue falls from diagnostics paint an unhealthy investment picture for retail value investors. One drug generates the primary revenue while management attempts to turn a profit mostly from diagnostics through deep cost-cutting and site closures. ...
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q4 2022 Earnings Call Feb 23, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q4 2022 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2022 Earnings Conference Call February 23, 2023, 16:30 ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Steven Rubin - EVP, Administration &am...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...